Protective Effect of Quercetin 3-O-Glucuronide against Cisplatin Cytotoxicity in Renal Tubular Cells

Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal injection, but its low bioavailability curtails its prospective clinical utility in oral therapy. We recently developed a micellar formulation (P-que...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Vol. 27; no. 4; p. 1319
Main Authors: Muñoz-Reyes, Daniel, Casanova, Alfredo G., González-Paramás, Ana María, Martín, Ángel, Santos-Buelga, Celestino, Morales, Ana I., López-Hernández, Francisco J., Prieto, Marta
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 15.02.2022
MDPI
Subjects:
ISSN:1420-3049, 1420-3049
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal injection, but its low bioavailability curtails its prospective clinical utility in oral therapy. We recently developed a micellar formulation (P-quercetin) with enhanced solubility and bioavailability, and identical nephroprotective properties. As a first aim, we herein evaluated the oral treatment with P-quercetin in rats, which displayed no nephroprotection. In order to unravel this discrepancy, quercetin and its main metabolites were measured by HPLC in the blood and urine after intraperitoneal and oral administrations. Whilst quercetin was absorbed similarly, the profile of its metabolites was different, which led us to hypothesize that nephroprotection might be exerted in vivo by a metabolic derivate. Consequently, we then aimed to evaluate the cytoprotective capacity of quercetin and its main metabolites (quercetin 3-O-glucoside, rutin, tamarixetin, isorhamnetin and quercetin 3-O-glucuronide) against cisplatin toxicity, in HK-2 and NRK-52E tubular cell lines. Cells were incubated for 6 h with quercetin, its metabolites or vehicle (pretreatment), and subsequently 18 h in cotreatment with 10–300 μM cisplatin. Immediately after treatment, cell cultures were subject to the MTT technique as an index of cytotoxicity and photographed under light microscopy for phenotypic assessment. Quercetin afforded no direct cytoprotection and quercetin-3-O-glucuronide was the only metabolite partially preventing the effect of cisplatin in cultured tubule cells. Our results identify a metabolic derivative of quercetin contributing to its nephroprotection and prompt to further explore exogenous quercetin-3-O-glucuronide in the prophylaxis of tubular nephrotoxicity.
AbstractList Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal injection, but its low bioavailability curtails its prospective clinical utility in oral therapy. We recently developed a micellar formulation (P-quercetin) with enhanced solubility and bioavailability, and identical nephroprotective properties. As a first aim, we herein evaluated the oral treatment with P-quercetin in rats, which displayed no nephroprotection. In order to unravel this discrepancy, quercetin and its main metabolites were measured by HPLC in the blood and urine after intraperitoneal and oral administrations. Whilst quercetin was absorbed similarly, the profile of its metabolites was different, which led us to hypothesize that nephroprotection might be exerted in vivo by a metabolic derivate. Consequently, we then aimed to evaluate the cytoprotective capacity of quercetin and its main metabolites (quercetin 3-O-glucoside, rutin, tamarixetin, isorhamnetin and quercetin 3-O-glucuronide) against cisplatin toxicity, in HK-2 and NRK-52E tubular cell lines. Cells were incubated for 6 h with quercetin, its metabolites or vehicle (pretreatment), and subsequently 18 h in cotreatment with 10–300 μM cisplatin. Immediately after treatment, cell cultures were subject to the MTT technique as an index of cytotoxicity and photographed under light microscopy for phenotypic assessment. Quercetin afforded no direct cytoprotection and quercetin-3-O-glucuronide was the only metabolite partially preventing the effect of cisplatin in cultured tubule cells. Our results identify a metabolic derivative of quercetin contributing to its nephroprotection and prompt to further explore exogenous quercetin-3-O-glucuronide in the prophylaxis of tubular nephrotoxicity.
Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal injection, but its low bioavailability curtails its prospective clinical utility in oral therapy. We recently developed a micellar formulation (P-quercetin) with enhanced solubility and bioavailability, and identical nephroprotective properties. As a first aim, we herein evaluated the oral treatment with P-quercetin in rats, which displayed no nephroprotection. In order to unravel this discrepancy, quercetin and its main metabolites were measured by HPLC in the blood and urine after intraperitoneal and oral administrations. Whilst quercetin was absorbed similarly, the profile of its metabolites was different, which led us to hypothesize that nephroprotection might be exerted in vivo by a metabolic derivate. Consequently, we then aimed to evaluate the cytoprotective capacity of quercetin and its main metabolites (quercetin 3- -glucoside, rutin, tamarixetin, isorhamnetin and quercetin 3- -glucuronide) against cisplatin toxicity, in HK-2 and NRK-52E tubular cell lines. Cells were incubated for 6 h with quercetin, its metabolites or vehicle (pretreatment), and subsequently 18 h in cotreatment with 10-300 μM cisplatin. Immediately after treatment, cell cultures were subject to the MTT technique as an index of cytotoxicity and photographed under light microscopy for phenotypic assessment. Quercetin afforded no direct cytoprotection and quercetin-3- -glucuronide was the only metabolite partially preventing the effect of cisplatin in cultured tubule cells. Our results identify a metabolic derivative of quercetin contributing to its nephroprotection and prompt to further explore exogenous quercetin-3- -glucuronide in the prophylaxis of tubular nephrotoxicity.
Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal injection, but its low bioavailability curtails its prospective clinical utility in oral therapy. We recently developed a micellar formulation (P-quercetin) with enhanced solubility and bioavailability, and identical nephroprotective properties. As a first aim, we herein evaluated the oral treatment with P-quercetin in rats, which displayed no nephroprotection. In order to unravel this discrepancy, quercetin and its main metabolites were measured by HPLC in the blood and urine after intraperitoneal and oral administrations. Whilst quercetin was absorbed similarly, the profile of its metabolites was different, which led us to hypothesize that nephroprotection might be exerted in vivo by a metabolic derivate. Consequently, we then aimed to evaluate the cytoprotective capacity of quercetin and its main metabolites (quercetin 3-O-glucoside, rutin, tamarixetin, isorhamnetin and quercetin 3-O-glucuronide) against cisplatin toxicity, in HK-2 and NRK-52E tubular cell lines. Cells were incubated for 6 h with quercetin, its metabolites or vehicle (pretreatment), and subsequently 18 h in cotreatment with 10-300 μM cisplatin. Immediately after treatment, cell cultures were subject to the MTT technique as an index of cytotoxicity and photographed under light microscopy for phenotypic assessment. Quercetin afforded no direct cytoprotection and quercetin-3-O-glucuronide was the only metabolite partially preventing the effect of cisplatin in cultured tubule cells. Our results identify a metabolic derivative of quercetin contributing to its nephroprotection and prompt to further explore exogenous quercetin-3-O-glucuronide in the prophylaxis of tubular nephrotoxicity.Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal injection, but its low bioavailability curtails its prospective clinical utility in oral therapy. We recently developed a micellar formulation (P-quercetin) with enhanced solubility and bioavailability, and identical nephroprotective properties. As a first aim, we herein evaluated the oral treatment with P-quercetin in rats, which displayed no nephroprotection. In order to unravel this discrepancy, quercetin and its main metabolites were measured by HPLC in the blood and urine after intraperitoneal and oral administrations. Whilst quercetin was absorbed similarly, the profile of its metabolites was different, which led us to hypothesize that nephroprotection might be exerted in vivo by a metabolic derivate. Consequently, we then aimed to evaluate the cytoprotective capacity of quercetin and its main metabolites (quercetin 3-O-glucoside, rutin, tamarixetin, isorhamnetin and quercetin 3-O-glucuronide) against cisplatin toxicity, in HK-2 and NRK-52E tubular cell lines. Cells were incubated for 6 h with quercetin, its metabolites or vehicle (pretreatment), and subsequently 18 h in cotreatment with 10-300 μM cisplatin. Immediately after treatment, cell cultures were subject to the MTT technique as an index of cytotoxicity and photographed under light microscopy for phenotypic assessment. Quercetin afforded no direct cytoprotection and quercetin-3-O-glucuronide was the only metabolite partially preventing the effect of cisplatin in cultured tubule cells. Our results identify a metabolic derivative of quercetin contributing to its nephroprotection and prompt to further explore exogenous quercetin-3-O-glucuronide in the prophylaxis of tubular nephrotoxicity.
Author Muñoz-Reyes, Daniel
Martín, Ángel
Casanova, Alfredo G.
González-Paramás, Ana María
Morales, Ana I.
Santos-Buelga, Celestino
López-Hernández, Francisco J.
Prieto, Marta
AuthorAffiliation 4 Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
5 National Network for Kidney Research REDINREN, RD016/0009/0025, Instituto de Salud Carlos III, 28029 Madrid, Spain
6 Polyphenols Research Group (GIP-USAL), Nutrition and Bromatology Unit, Faculty of Pharmacy, Universidad de Salamanca, 37007 Salamanca, Spain; paramas@usal.es (A.M.G.-P.); csb@usal.es (C.S.-B.)
3 Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), 37007 Salamanca, Spain
1 Toxicology Unit, Universidad de Salamanca, 37007 Salamanca, Spain; danimr@usal.es (D.M.-R.); alfredogcp@usal.es (A.G.C.); amorales@usal.es (A.I.M.); martapv@usal.es (M.P.)
2 Department of Physiology and Pharmacology, Universidad de Salamanca, 37007 Salamanca, Spain
7 High Pressure Processes Group, BioEcoUVa, Bioeconomy Research Institute, Department of Chemical Engineering and Environmental Technology, Universidad de Valladolid, 47011 Valladolid, Spain; mamaan@iq.uva.es
AuthorAffiliation_xml – name: 3 Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), 37007 Salamanca, Spain
– name: 2 Department of Physiology and Pharmacology, Universidad de Salamanca, 37007 Salamanca, Spain
– name: 1 Toxicology Unit, Universidad de Salamanca, 37007 Salamanca, Spain; danimr@usal.es (D.M.-R.); alfredogcp@usal.es (A.G.C.); amorales@usal.es (A.I.M.); martapv@usal.es (M.P.)
– name: 4 Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
– name: 6 Polyphenols Research Group (GIP-USAL), Nutrition and Bromatology Unit, Faculty of Pharmacy, Universidad de Salamanca, 37007 Salamanca, Spain; paramas@usal.es (A.M.G.-P.); csb@usal.es (C.S.-B.)
– name: 7 High Pressure Processes Group, BioEcoUVa, Bioeconomy Research Institute, Department of Chemical Engineering and Environmental Technology, Universidad de Valladolid, 47011 Valladolid, Spain; mamaan@iq.uva.es
– name: 5 National Network for Kidney Research REDINREN, RD016/0009/0025, Instituto de Salud Carlos III, 28029 Madrid, Spain
Author_xml – sequence: 1
  givenname: Daniel
  orcidid: 0000-0001-8464-1996
  surname: Muñoz-Reyes
  fullname: Muñoz-Reyes, Daniel
– sequence: 2
  givenname: Alfredo G.
  orcidid: 0000-0002-0725-6637
  surname: Casanova
  fullname: Casanova, Alfredo G.
– sequence: 3
  givenname: Ana María
  orcidid: 0000-0001-5477-0703
  surname: González-Paramás
  fullname: González-Paramás, Ana María
– sequence: 4
  givenname: Ángel
  surname: Martín
  fullname: Martín, Ángel
– sequence: 5
  givenname: Celestino
  orcidid: 0000-0001-6592-5299
  surname: Santos-Buelga
  fullname: Santos-Buelga, Celestino
– sequence: 6
  givenname: Ana I.
  orcidid: 0000-0001-6836-6138
  surname: Morales
  fullname: Morales, Ana I.
– sequence: 7
  givenname: Francisco J.
  orcidid: 0000-0001-7778-7495
  surname: López-Hernández
  fullname: López-Hernández, Francisco J.
– sequence: 8
  givenname: Marta
  orcidid: 0000-0002-2540-4461
  surname: Prieto
  fullname: Prieto, Marta
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35209106$$D View this record in MEDLINE/PubMed
BookMark eNp9kltrFTEQx4NU7EU_gC-y4Isvq7ntJS-CLG0tFKpSn0M2OznmkLM55lJ6vr3ZnlraCr4kk8lv_kzyn2N0MPsZEHpL8EfGBP608Q50dhBphzlhRLxAR4RTXDPMxcGj-BAdx7jGmBJOmlfokDUUC4LbIzR9Cz6BTvYGqlNjSlR5U33PEDQkO1esvqrPXdY5-NlOUKmVsnNM1WDj1qmFGHbJJ39rtU27qpx_wKxcdZ3H7FSoBnAuvkYvjXIR3tzvJ-jn2en18LW-vDq_GL5c1poLlmpNRwHNyFinOaFY6R6oWXK8453oW2rMNLaN1oYoNSkCjRh5Y0bOBeWcKnaCLva6k1druQ12o8JOemXlXcKHlVQhWe1AMhCipYQ1XLS8p7SsegTDeUfGrlVN0fq819rmcQOThjkF5Z6IPr2Z7S-58jey73vMSFsEPtwLBP87Q0xyY6Mu36Fm8DlK2jLWN4K0uKDvn6Frn0P5xj1FWfFr6ejd444eWvlrZgHIHtDBxxjAPCAEy2Vg5D8DU2q6ZzXFx-KrXx5l3X8q_wB6Bshc
CitedBy_id crossref_primary_10_1039_D5MD00426H
crossref_primary_10_3390_ijms23137227
crossref_primary_10_3390_ph16101419
crossref_primary_10_1002_cbdv_202301493
crossref_primary_10_3389_fphar_2025_1492517
crossref_primary_10_1007_s44339_025_00029_7
crossref_primary_10_3390_pr11092721
crossref_primary_10_4103_wjtcm_wjtcm_72_24
crossref_primary_10_1016_j_biopha_2022_113836
crossref_primary_10_3390_ani13172745
crossref_primary_10_3390_molecules27134144
crossref_primary_10_1155_2022_3997190
crossref_primary_10_2147_CCID_S478666
Cites_doi 10.1038/nrneph.2010.16
10.1038/sj.ki.5002786
10.1079/BJN20061809
10.1002/mnfr.201100378
10.1080/10408390600846291
10.1016/j.ejphar.2014.07.025
10.1111/1541-4337.12342
10.1002/jsfa.5697
10.1016/j.neurobiolaging.2016.12.024
10.1093/ndt/12.12.2478
10.1093/ndt/gfq840
10.1093/toxsci/kfr098
10.3390/antiox10060909
10.1093/ndt/gfr195
10.1007/s40620-017-0392-z
10.2174/0929867325666180706104829
10.2174/1568011033353470
10.1186/cc2872
10.1039/c2fo10268d
10.1016/j.bcp.2011.01.004
10.1007/s002800100318
10.1371/journal.pone.0032673
10.1186/cc5713
10.1124/jpet.102.040220
10.1021/ie5001136
10.1016/j.phrs.2014.07.005
10.1080/10715760600823128
10.1002/jsfa.8197
10.3390/ijms22020729
10.1038/srep35460
10.1097/MAJ.0b013e31812dfe1e
10.1016/j.bcp.2017.08.017
10.1016/j.bbrc.2018.09.018
10.1016/j.tifs.2016.07.004
10.3109/10408444.2011.602662
10.3390/ijms18030531
10.1258/000456307779595940
10.1016/j.cbi.2011.07.002
10.12659/MSM.909259
10.1039/C4FO00413B
10.1016/j.fct.2017.06.047
10.1124/dmd.116.069575
10.1038/sj.bjp.0704064
ContentType Journal Article
Copyright 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 by the authors. 2022
Copyright_xml – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 by the authors. 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/molecules27041319
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

CrossRef
MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1420-3049
ExternalDocumentID oai_doaj_org_article_3e99621354964822964cbef4471b76a5
PMC8880316
35209106
10_3390_molecules27041319
Genre Journal Article
GrantInformation_xml – fundername: Strategic Research Programs for Units of Excellence from Junta de Castilla y León
  grantid: CLU-2018-04
– fundername: Spanish Ministerio de Ciencia, Innovación
  grantid: Project PID2019-106167RB-I00
– fundername: Junta de Castilla y León
  grantid: VA225U14
– fundername: Fundación FUESCYL-Banco Santander
  grantid: Ed. 2014-2015 Desafío UNIV-EMP
– fundername: Consejería de Educación, Junta de Castilla y León
  grantid: Project SA093P20
– fundername: Fundación General de la Universidad de Salamanca, Fondo Europeo de Desarrollo Regional (FEDER) y la Junta de Castilla y León
  grantid: Ed. 2015 Lanzadera TC
GroupedDBID ---
0R~
123
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIWK
ACPRK
ACUHS
AEGXH
AENEX
AFFHD
AFKRA
AFPKN
AFRAH
AFZYC
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
E3Z
EBD
EMOBN
ESTFP
ESX
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
HZ~
I09
IAO
IHR
ITC
KQ8
LK8
M1P
MODMG
O-U
O9-
OK1
P2P
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RPM
SV3
TR2
TUS
UKHRP
~8M
3V.
ABJCF
ALIPV
BBNVY
BHPHI
CGR
CUY
CVF
ECM
EIF
HCIFZ
KB.
M7P
M~E
NPM
PDBOC
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c493t-c2b9e5b337c4120ac8e2f2b9e47479862ffdb65ccf1aada1e59b45fb4492442a3
IEDL.DBID 7X7
ISICitedReferencesCount 12
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000764337100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1420-3049
IngestDate Tue Oct 14 18:58:31 EDT 2025
Tue Nov 04 01:48:14 EST 2025
Mon Sep 08 06:01:34 EDT 2025
Tue Oct 07 07:17:34 EDT 2025
Wed Feb 19 02:27:38 EST 2025
Sat Nov 29 07:17:08 EST 2025
Tue Nov 18 20:57:21 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords quercetin
quercetin 3-O-glucuronide
cytoprotection
nephrotoxicity
cisplatin
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c493t-c2b9e5b337c4120ac8e2f2b9e47479862ffdb65ccf1aada1e59b45fb4492442a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6836-6138
0000-0002-2540-4461
0000-0002-0725-6637
0000-0001-7778-7495
0000-0001-8464-1996
0000-0001-5477-0703
0000-0001-6592-5299
OpenAccessLink https://www.proquest.com/docview/2633233525?pq-origsite=%requestingapplication%
PMID 35209106
PQID 2633233525
PQPubID 2032355
ParticipantIDs doaj_primary_oai_doaj_org_article_3e99621354964822964cbef4471b76a5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8880316
proquest_miscellaneous_2633859160
proquest_journals_2633233525
pubmed_primary_35209106
crossref_primary_10_3390_molecules27041319
crossref_citationtrail_10_3390_molecules27041319
PublicationCentury 2000
PublicationDate 20220215
PublicationDateYYYYMMDD 2022-02-15
PublicationDate_xml – month: 2
  year: 2022
  text: 20220215
  day: 15
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Molecules (Basel, Switzerland)
PublicationTitleAlternate Molecules
PublicationYear 2022
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Baral (ref_30) 2017; 52
Lash (ref_24) 2002; 303
Deiana (ref_32) 2011; 193
Gluba (ref_9) 2010; 6
Wang (ref_10) 2016; 56
Nemeth (ref_27) 2007; 47
Vanholder (ref_20) 2011; 26
Manohar (ref_2) 2018; 31
Morales (ref_3) 2011; 26
Steffen (ref_35) 2021; 146
Yang (ref_36) 2016; 6
Kuhlmann (ref_4) 1997; 12
DeHaan (ref_8) 2001; 48
ref_12
Duarte (ref_42) 2006; 40
Russo (ref_11) 2014; 5
(ref_13) 2019; 26
Almeida (ref_26) 2018; 17
Menendez (ref_38) 2011; 55
Mullen (ref_44) 2006; 96
Duarte (ref_37) 2012; 92
Chen (ref_31) 2003; 3
ref_16
Perez (ref_39) 2014; 89
Cueva (ref_45) 2017; 97
Yao (ref_1) 2007; 334
Prieto (ref_15) 2017; 107
Pabla (ref_6) 2008; 73
Khwaja (ref_19) 2012; 120
Asai (ref_33) 2018; 504
Morales (ref_22) 2011; 41
Galindo (ref_25) 2012; 3
Piedrafita (ref_5) 2011; 122
Diskin (ref_21) 2007; 44
ref_23
Semenova (ref_28) 2017; 145
ref_40
Mehta (ref_18) 2007; 11
Iwamura (ref_34) 2016; 44
Dasari (ref_7) 2014; 740
Bellomo (ref_17) 2004; 8
Yang (ref_14) 2018; 24
Wong (ref_29) 2011; 81
Duarte (ref_41) 2001; 133
Fraile (ref_43) 2014; 53
References_xml – volume: 6
  start-page: 224
  year: 2010
  ident: ref_9
  article-title: The Role of Toll-like Receptors in Renal Diseases
  publication-title: Nat. Rev. Nephrol.
  doi: 10.1038/nrneph.2010.16
– volume: 73
  start-page: 994
  year: 2008
  ident: ref_6
  article-title: Cisplatin Nephrotoxicity: Mechanisms and Renoprotective Strategies
  publication-title: Kidney Int.
  doi: 10.1038/sj.ki.5002786
– volume: 96
  start-page: 107
  year: 2006
  ident: ref_44
  article-title: Absorption, Excretion and Metabolite Profiling of Methyl-, Glucuronyl-, Glucosyl- and Sulpho-Conjugates of Quercetin in Human Plasma and Urine after Ingestion of Onions
  publication-title: Br. J. Nutr.
  doi: 10.1079/BJN20061809
– volume: 55
  start-page: 1780
  year: 2011
  ident: ref_38
  article-title: Vascular Deconjugation of Quercetin Glucuronide: The Flavonoid Paradox Revealed?
  publication-title: Mol. Nutr. Food Res.
  doi: 10.1002/mnfr.201100378
– volume: 47
  start-page: 397
  year: 2007
  ident: ref_27
  article-title: Food Content, Processing, Absorption and Metabolism of Onion Flavonoids
  publication-title: Crit. Rev. Food Sci. Nutr.
  doi: 10.1080/10408390600846291
– volume: 120
  start-page: c179
  year: 2012
  ident: ref_19
  article-title: KDIGO Clinical Practice Guidelines for Acute Kidney Injury
  publication-title: Nephron
– volume: 740
  start-page: 364
  year: 2014
  ident: ref_7
  article-title: Cisplatin in Cancer Therapy: Molecular Mechanisms of Action
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2014.07.025
– volume: 17
  start-page: 714
  year: 2018
  ident: ref_26
  article-title: Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation: Variability in Quercetin Bioavailability
  publication-title: Compr. Rev. Food Sci. Food Saf.
  doi: 10.1111/1541-4337.12342
– volume: 92
  start-page: 1822
  year: 2012
  ident: ref_37
  article-title: The Flavonoid Paradox: Conjugation and Deconjugation as Key Steps for the Biological Activity of Flavonoids: The Flavonoid Paradox
  publication-title: J. Sci. Food Agric.
  doi: 10.1002/jsfa.5697
– volume: 146
  start-page: 1009
  year: 2021
  ident: ref_35
  article-title: Analgesic Drug Therapy in Kidney Patients
  publication-title: Dtsch. Med. Wochenschr.
– volume: 52
  start-page: 39
  year: 2017
  ident: ref_30
  article-title: Quercetin-3-O-Glucuronide Promotes the Proliferation and Migration of Neural Stem Cells
  publication-title: Neurobiol. Aging
  doi: 10.1016/j.neurobiolaging.2016.12.024
– volume: 12
  start-page: 2478
  year: 1997
  ident: ref_4
  article-title: Insights into Potential Cellular Mechanisms of Cisplatin Nephrotoxicity and Their Clinical Application
  publication-title: Nephrol. Dial. Transplant.
  doi: 10.1093/ndt/12.12.2478
– volume: 26
  start-page: 3211
  year: 2011
  ident: ref_20
  article-title: Serum Urea Concentration Is Probably Not Related to Outcome in ICU Patients with AKI and Renal Replacement Therapy
  publication-title: Nephrol. Dial. Transplant.
  doi: 10.1093/ndt/gfq840
– volume: 122
  start-page: 73
  year: 2011
  ident: ref_5
  article-title: Necrotic Concentrations of Cisplatin Activate the Apoptotic Machinery but Inhibit Effector Caspases and Interfere with the Execution of Apoptosis
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfr098
– ident: ref_12
  doi: 10.3390/antiox10060909
– volume: 26
  start-page: 3484
  year: 2011
  ident: ref_3
  article-title: Quercetin Reduces Cisplatin Nephrotoxicity in Rats without Compromising Its Anti-Tumour Activity
  publication-title: Nephrol. Dial. Transplant.
  doi: 10.1093/ndt/gfr195
– volume: 31
  start-page: 15
  year: 2018
  ident: ref_2
  article-title: Cisplatin Nephrotoxicity: A Review of the Literature
  publication-title: J. Nephrol.
  doi: 10.1007/s40620-017-0392-z
– volume: 26
  start-page: 6976
  year: 2019
  ident: ref_13
  article-title: The Mechanisms Behind the Biological Activity of Flavonoids
  publication-title: Curr. Med. Chem.
  doi: 10.2174/0929867325666180706104829
– volume: 3
  start-page: 139
  year: 2003
  ident: ref_31
  article-title: Glucuronides in Anti-Cancer Therapy
  publication-title: Curr. Med. Chem.-Anti-Cancer Agents
  doi: 10.2174/1568011033353470
– volume: 8
  start-page: R204
  year: 2004
  ident: ref_17
  article-title: Acute Renal Failure—Definition, Outcome Measures, Animal Models, Fluid Therapy and Information Technology Needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
  publication-title: Crit Care
  doi: 10.1186/cc2872
– volume: 3
  start-page: 643
  year: 2012
  ident: ref_25
  article-title: Different Cardiovascular Protective Effects of Quercetin Administered Orally or Intraperitoneally in Spontaneously Hypertensive Rats
  publication-title: Food Funct.
  doi: 10.1039/c2fo10268d
– volume: 81
  start-page: 942
  year: 2011
  ident: ref_29
  article-title: Flavonoid Conjugates Interact with Organic Anion Transporters (OATs) and Attenuate Cytotoxicity of Adefovir Mediated by Organic Anion Transporter 1 (OAT1/SLC22A6)
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2011.01.004
– volume: 48
  start-page: 383
  year: 2001
  ident: ref_8
  article-title: Regulation of P53 Target Gene Expression by Cisplatin-Induced Extracellular Signal-Regulated Kinase
  publication-title: Cancer Chemother. Pharm.
  doi: 10.1007/s002800100318
– ident: ref_40
  doi: 10.1371/journal.pone.0032673
– volume: 11
  start-page: R31
  year: 2007
  ident: ref_18
  article-title: Acute Kidney Injury Network: Report of an Initiative to Improve Outcomes in Acute Kidney Injury
  publication-title: Crit Care
  doi: 10.1186/cc5713
– volume: 303
  start-page: 476
  year: 2002
  ident: ref_24
  article-title: Protection of NRK-52E Cells, a Rat Renal Proximal Tubular Cell Line, from Chemical-Induced Apoptosis by Overexpression of a Mitochondrial Glutathione Transporter
  publication-title: J. Pharm. Exp.
  doi: 10.1124/jpet.102.040220
– volume: 53
  start-page: 4318
  year: 2014
  ident: ref_43
  article-title: Enhanced Delivery of Quercetin by Encapsulation in Poloxamers by Supercritical Antisolvent Process
  publication-title: Ind. Eng. Chem. Res.
  doi: 10.1021/ie5001136
– volume: 89
  start-page: 11
  year: 2014
  ident: ref_39
  article-title: The Flavonoid Quercetin Induces Acute Vasodilator Effects in Healthy Volunteers: Correlation with Beta-Glucuronidase Activity
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2014.07.005
– volume: 40
  start-page: 1054
  year: 2006
  ident: ref_42
  article-title: Endothelial Function and Cardiovascular Disease: Effects of Quercetin and Wine Polyphenols
  publication-title: Free Radic. Res.
  doi: 10.1080/10715760600823128
– volume: 97
  start-page: 3433
  year: 2017
  ident: ref_45
  article-title: Chemical Characterization and in Vitro Colonic Fermentation of Grape Pomace Extracts
  publication-title: J. Sci. Food Agric.
  doi: 10.1002/jsfa.8197
– ident: ref_16
  doi: 10.3390/ijms22020729
– volume: 6
  start-page: 35460
  year: 2016
  ident: ref_36
  article-title: Pharmacokinetic Comparison between Quercetin and Quercetin 3-O-β-Glucuronide in Rats by UHPLC-MS/MS
  publication-title: Sci. Rep.
  doi: 10.1038/srep35460
– volume: 334
  start-page: 115
  year: 2007
  ident: ref_1
  article-title: Cisplatin Nephrotoxicity: A Review
  publication-title: Am. J. Med. Sci.
  doi: 10.1097/MAJ.0b013e31812dfe1e
– volume: 145
  start-page: 147
  year: 2017
  ident: ref_28
  article-title: Distribution, Properties, and Inhibitor Sensitivity of Zebrafish Catechol-O-Methyl Transferases (COMT)
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2017.08.017
– volume: 504
  start-page: 538
  year: 2018
  ident: ref_33
  article-title: Indoxyl Glucuronide, a Protein-Bound Uremic Toxin, Inhibits Hypoxia-Inducible Factor—dependent Erythropoietin Expression through Activation of Aryl Hydrocarbon Receptor
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2018.09.018
– volume: 56
  start-page: 21
  year: 2016
  ident: ref_10
  article-title: The Biological Activities, Chemical Stability, Metabolism and Delivery Systems of Quercetin: A Review
  publication-title: Trends Food Sci. Technol.
  doi: 10.1016/j.tifs.2016.07.004
– volume: 41
  start-page: 803
  year: 2011
  ident: ref_22
  article-title: An Integrative View of the Pathophysiological Events Leading to Cisplatin Nephrotoxicity
  publication-title: Crit. Rev. Toxicol.
  doi: 10.3109/10408444.2011.602662
– ident: ref_23
  doi: 10.3390/ijms18030531
– volume: 44
  start-page: 16
  year: 2007
  ident: ref_21
  article-title: Creatinine and Glomerular Filtration Rate: Evolution of an Accommodation
  publication-title: Ann. Clin. Biochem.
  doi: 10.1258/000456307779595940
– volume: 193
  start-page: 232
  year: 2011
  ident: ref_32
  article-title: Hydroxytyrosol Glucuronides Protect Renal Tubular Epithelial Cells against H2O2 Induced Oxidative Damage
  publication-title: Chem.-Biol. Interact.
  doi: 10.1016/j.cbi.2011.07.002
– volume: 24
  start-page: 4760
  year: 2018
  ident: ref_14
  article-title: Quercetin Treatment Improves Renal Function and Protects the Kidney in a Rat Model of Adenine-Induced Chronic Kidney Disease
  publication-title: Med. Sci. Monit.
  doi: 10.12659/MSM.909259
– volume: 5
  start-page: 2393
  year: 2014
  ident: ref_11
  article-title: The Pleiotropic Flavonoid Quercetin: From Its Metabolism to the Inhibition of Protein Kinases in Chronic Lymphocytic Leukemia
  publication-title: Food Funct.
  doi: 10.1039/C4FO00413B
– volume: 107
  start-page: 226
  year: 2017
  ident: ref_15
  article-title: Differential Effect of Quercetin on Cisplatin-Induced Toxicity in Kidney and Tumor Tissues
  publication-title: Food Chem. Toxicol.
  doi: 10.1016/j.fct.2017.06.047
– volume: 44
  start-page: 888
  year: 2016
  ident: ref_34
  article-title: Zomepirac Acyl Glucuronide Is Responsible for Zomepirac-Induced Acute Kidney Injury in Mice
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.116.069575
– volume: 133
  start-page: 117
  year: 2001
  ident: ref_41
  article-title: Antihypertensive Effects of the Flavonoid Quercetin in Spontaneously Hypertensive Rats: Quercetin and Hypertension
  publication-title: Br. J. Pharmacol.
  doi: 10.1038/sj.bjp.0704064
SSID ssj0021415
Score 2.414849
Snippet Quercetin, a flavonoid with promising therapeutic potential, has been shown to protect from cisplatin nephrotoxicity in rats following intraperitoneal...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1319
SubjectTerms Animals
Apoptosis
Bioavailability
Cell division
Cell Line
Cells, Cultured
Chemotherapy
Chromatography, High Pressure Liquid
cisplatin
Cisplatin - adverse effects
Cisplatin - pharmacology
Creatinine
cytoprotection
Cytoprotection - drug effects
Cytotoxicity
Drug dosages
Epithelial Cells - drug effects
Flavonoids
Glomerular Filtration Rate
Kidney Function Tests - methods
Kidney Tubules - cytology
Kidney Tubules - drug effects
Kinases
Metabolites
nephrotoxicity
Oral administration
Plasma
Protective Agents - pharmacology
quercetin
Quercetin - analogs & derivatives
Quercetin - pharmacology
quercetin 3-O-glucuronide
Rats
Small intestine
Urine
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9UwEA6yLOhF_G11VyJ4EsK2SZo2Ry27epB1lVX2VtJ0qoVnu2xb0f9-Z5q-x3sqevHYJKVpZjIzH5l8w9gLnJwCVAShba6Erl0irMys0C4hsg_p4zlB9vO77PQ0v7iwZ1ulvignLNADh4U7UoARuUwU4hijiZ3caF9Bo9GoVplxM3tpnNk1mFqgVoJ-KZxhKgT1R99CqVkYZBaj1SZanS0vNJP1_ynC_DVRcsvznNxht5eQkb8KU73LbkB3j90s1pXa7rP6LJAtoOHigY2Y9w3_MFHOyth2XIn34s1q8hPx4NbA3RfXYlTIi3a4pFS4jhc_x37sf7QeY3KOzx-Bvng-VZSkygtYrYYH7NPJ8XnxVizVE4TXVo3Cy8pCWimVeZ3I2PkcZENtGhGERSDTNHVlUu-bxDmUEaS20mlTaY2QTEunHrK9ru_gMeO4S2tlrMfopdY2bmyaA5Bbg8rXuYGIxevVLP1CLU4VLlYlQgwSQPmbACL2cvPKZeDV-Nvg1ySizUCixJ4bUFHKRVHKfylKxA7WAi6XfTqU0igl6doZdj_fdKP46NjEddBPYQyx_Jk4Yo-CPmxmoiiLCFF1xLIdTdmZ6m5P136dWbxztJwqMU_-x789ZbckXcugQjXpAdsbryY4ZPv--9gOV8_mrXEN9FgUZw
  priority: 102
  providerName: Directory of Open Access Journals
Title Protective Effect of Quercetin 3-O-Glucuronide against Cisplatin Cytotoxicity in Renal Tubular Cells
URI https://www.ncbi.nlm.nih.gov/pubmed/35209106
https://www.proquest.com/docview/2633233525
https://www.proquest.com/docview/2633859160
https://pubmed.ncbi.nlm.nih.gov/PMC8880316
https://doaj.org/article/3e99621354964822964cbef4471b76a5
Volume 27
WOSCitedRecordID wos000764337100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1420-3049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0021415
  issn: 1420-3049
  databaseCode: DOA
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1420-3049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0021415
  issn: 1420-3049
  databaseCode: 7X7
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1420-3049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0021415
  issn: 1420-3049
  databaseCode: BENPR
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1420-3049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0021415
  issn: 1420-3049
  databaseCode: PIMPY
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BiwQX3tBAWRmJE1LUxHYePiEatYAEy1IVtJwix3FKpG2ybBIE_56ZJLvtAuqFSyTHjjLSjMfz2eNvAF6gcMKiIbhSxcKVufZdxSPlSu0T2Qc3Xp8g--V9NJ3G87majRtuzZhWufaJvaPOa0N75Ac8FILTBaHg1fK7S1Wj6HR1LKFxHXapbDbZeTS_AFw-rk7DSaZAaH9wPhSctQ2PPPTdRK5zaS3qKfv_FWf-mS55af05vvO_kt-F22PkyV4PpnIPrtnqPtxM1gXfHkA-Gzgb0P-xgdSY1QX71FHqS1tWTLgf3TeLznREp5tbps90icElS8pmSRl1FUt-tXVb_ywNhvYM2yeW_njaZZTryhK7WDQP4fPx0Wny1h2LMLhGKtG6hmfKBpkQkZE-97SJLS_onUQgohAPFUWehYExha81qtoGKpNBkUmJyE5yLR7BTlVXdg8YTvZchMpgEJRL5RUqiK2l1dFmJo9D64C3VkdqRoZyKpSxSBGpkAbTvzTowMvNJ8uBnuOqwYek481AYtbuX9Srs3ScqKmwiAC5LxA3h5LY8ENpMltIFDOLQh04sL_WcjpO9ya9ULEDzzfdqD46fdGVrbthDJEFhp4DjweD2kgiKBkJwbkD0ZapbYm63VOV33oy8BgdsPDDJ1eL9RRucbq3QZVsgn3YaVedfQY3zI-2bFaTftb0z3gCu4dH09nJpN-cwNbs3YfZ199ThSkV
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VglQuvKGBAkaCC1LUxHYePiAEC6VVl6WgpdpbSBynjbQkyyYB-qf4jcwkm20XUG89cIzjJJP48zzi8TcAT1E4YRAItlShsGUau7bigbJl7BLZB9dOmyB7OAxGo3AyUQdr8KvfC0Nplb1ObBV1Wmr6R77NfSE4bRDyXs6-2VQ1ilZX-xIaHSz2zckPDNmqF3tvcHyfcb7zdjzYtRdVBWwtlahtzRNlvESIQEuXO7EODc-oTaJnrdDBz7I08T2tMzeOUXbjqUR6WSIlhiqSxwLvewkuox4PKNgLJqcBnovWsFs5FUI521-7Arem4oGDtoLIfM7YvrZEwL_82j_TM8_Yu53r_9uXugHXFp41e9VNhZuwZopbsDHoC9rdhvSg46RA_c460mZWZuxjQ6k9dV4wYX-w300b3RBdcGpYfBTn6DyzQV7NKGOwYIOTuqzLn7nG0IXh8SdDTxw3CeXysoGZTqs78PlCXvIurBdlYTaBoTJLha80OnmpVE6mvNAYsv4m0WnoGwucfvgjvWBgp0Ig0wgjMUJM9BdiLHi-vGTW0Y-c1_k1YWrZkZjD24ZyfhQtFFEkDEa43BWeVL4ktn9f6sRkEsVMAj_2LNjqURUt1FkVnULKgifL0zh8tLoUF6Zsuj5Ehug7FtzrALyURFCylev4FgQr0F4RdfVMkR-3ZOchGhjh-vfPF-sxbOyO3w-j4d5o_wFc5bRHhar2eFuwXs8b8xCu6O91Xs0ftTOWwZeLBv5vS1CCRA
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bj5NAFD5Zu0Z98X5BVx0TfTEhhZnhMg_GaNdqs2utZjXrE8IwrCQVagF1_5q_znMK1F01-7YPPhYGeoCPc2HOfB_AQzROGASCLVUobJnGrq14oGwZu0T2wbWzapD9sBtMp-H-vpptwM9-LQy1VfY-ceWo01LTN_Ih94XgtEDIG2ZdW8Rse_x08dUmBSmaae3lNFqI7JjD71i-VU8m2_isH3E-frE3emV3CgO2lkrUtuaJMl4iRKCly51Yh4ZntE1ilq0w2c-yNPE9rTM3jvE6jKcS6WWJlFi2SB4LPO8Z2MTBkg9gczZ5Pfu4LvdcjI3tPKoQyhl-aeVuTcUDByMHUfsciYQrwYB_Zbl_NmseiX7jS__zfbsMF7ucmz1rX5IrsGGKq3B-1EvdXYN01rJVoOdnLZ0zKzP2tqGmnzovmLDf2C_njW6ISDg1LD6Ic0yr2SivFtRLWLDRYV3W5Y9cY1HD8Pc7Q_-41yTU5ctGZj6vrsP7U7nIGzAoysLcAoZuLhW-0pj-pVI5mfJCYygvMIlOQ99Y4PRQiHTHzU4SIfMIazRCT_QXeix4vD5k0RKTnDT4OeFrPZA4xVcbyuVB1LmoSBisfbkrPKl8SToAvtSJySSamQR-7Fmw1SMs6hxdFf2GlwUP1rvx8dG8U1yYsmnHEE2i71hwswXz2hJBbViu41sQHIP5MVOP7ynyzysa9BBDj3D92yebdR_OId6j3cl05w5c4LR4heR8vC0Y1MvG3IWz-ludV8t73evL4NNpI_8XpMqMkw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protective+Effect+of+Quercetin+3-O-Glucuronide+against+Cisplatin+Cytotoxicity+in+Renal+Tubular+Cells&rft.jtitle=Molecules+%28Basel%2C+Switzerland%29&rft.au=Mu%C3%B1oz-Reyes%2C+Daniel&rft.au=Casanova%2C+Alfredo+G&rft.au=Gonz%C3%A1lez-Param%C3%A1s%2C+Ana+Mar%C3%ADa&rft.au=Mart%C3%ADn%2C+%C3%81ngel&rft.date=2022-02-15&rft.pub=MDPI+AG&rft.eissn=1420-3049&rft.volume=27&rft.issue=4&rft.spage=1319&rft_id=info:doi/10.3390%2Fmolecules27041319&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1420-3049&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1420-3049&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1420-3049&client=summon